In a human study, patients with relapsing-remitting multiple sclerosis (RRMS) were examined for IL-22 levels in their sera at various time intervals with or without treatment using interferon β-1a, interferon β-1b, and fingolimod. The gene discussed is IL22; the disease is relapsing-remitting multiple sclerosis.